The Andhra Pradesh High Court has reportedly ordered an interim status quo on the $4 billion deal between Sun Pharma and Ranbaxy Laboratories. The order was in response to a petition filed by some individual investors, who alleged insider trading in Ranbaxy shares.
The petitioner is seeking action against Sun Pharma and its wholly-owned arm Silverstreet Developers LLP. Sun Pharma had earlier announced that its subsidiary’s share purchase was being annulled as part of the merger deal.
Further, the court has issued notices to SEBI, BSE, NSE, and the three companies (Sun Pharma, Silverstreet and Ranbaxy) to respond to the petitioners’ charges.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: